Entera Bio Ltd. Net Profit Margin

Net Profit Margin of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Profit Margin growth rates and interactive chart. The net profit margin is equal to how much net income or profit is generated as a percentage of revenue. Net profit margin is the ratio of net profits (or net income) to revenues for a company. Net profit margin is typically expressed as a percentage. The net profit margin illustrates how much of each dollar in revenue collected by a company translates into profit.

Highlights and Quick Summary

  • Net Profit Margin for the quarter ending June 29, 2020 was -6134.62% (a -11.7% decrease compared to previous quarter)
  • Year-over-year quarterly Net Profit Margin increased by 22.94%
  • Annual Net Profit Margin for 2019 was -4574.15% (a 121.96% increase from previous year)
  • Annual Net Profit Margin for 2018 was -2060.8% (a -Infinity% decrease from previous year)
  • Twelve month Net Profit Margin ending June 29, 2020 was -4899.22% (a 27.07% increase compared to previous quarter)
  • Twelve month trailing Net Profit Margin decreased by -Infinity% year-over-year
Trailing Net Profit Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-4899.22% -3855.4% -1466.71% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Profit Margin of Entera Bio Ltd.

Most recent Net Profit Marginof ENTX including historical data for past 10 years.

Interactive Chart of Net Profit Margin of Entera Bio Ltd.

Entera Bio Ltd. Net Profit Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -6134.62% -6947.62%
2019 -3372.55% -4990.0% -1845.95% 0.0% -4574.15%
2018 -529.0% 0.0% 0.0% 0.0% -2060.8%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.